Literature DB >> 22020336

p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.

S Fransson1, A Uv, H Eriksson, M K Andersson, Y Wettergren, M Bergo, K Ejeskär.   

Abstract

The phosphatidylinositol 3-kinases (PI3Ks) regulate cell growth, proliferation and survival, and are frequently affected in human cancer. PI3K is composed of a catalytic subunit, p110, and a regulatory subunit, p85. The PI3K catalytic subunit p110δ is encoded by PIK3CD and contains p85- and RAS-binding domains, and a kinase domain. Here we present an alternatively spliced PIK3CD transcript encoding a previously unknown protein, p37δ, and demonstrate that this protein is expressed in human ovarian and colorectal tumors. p37δ retains the p85-binding domain and a fraction of the RAS-binding domain, lacks the catalytic domain, and has a unique carboxyl-terminal region. In contrast to p110δ, which stabilizes p85, p37δ promoted p85 sequestering. Despite the truncated RAS-binding domain, p37δ bound to RAS and we found a strong positive correlation between the protein levels of p37δ and RAS. Overexpressing p37δ, but not p110δ, increased the proliferation and invasive properties of HEK-293 cells and mouse embryonic fibroblasts. Cells overexpressing p37δ showed a quicker phosphorylation response of AKT and ERK1/2 following serum stimulation. Ubiquitous expression of human p37δ in the fruit fly increased body size, DNA content and phosphorylated ERK1/2 levels. Thus, p37δ appears to be a new tumor-specific isoform of p110δ with growth-promoting properties.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020336     DOI: 10.1038/onc.2011.492

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.

Authors:  Susanne Fransson; Katarina Ejeskär
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

2.  p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.

Authors:  Aditi Chaudhari; Daniel Krumlinde; Annika Lundqvist; Levent M Akyürek; Sashidhar Bandaru; Kristina Skålén; Marcus Ståhlman; Jan Borén; Yvonne Wettergren; Katarina Ejeskär; Victoria Rotter Sopasakis
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

3.  The physical influence of inositides-a disproportionate effect?

Authors:  Samuel Furse
Journal:  J Chem Biol       Date:  2014-07-20

Review 4.  Targeting the PI3K pathway for cancer therapy.

Authors:  Navid Sadeghi; David E Gerber
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

5.  An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.

Authors:  Maria Giuseppina Baratta; Anna C Schinzel; Yaara Zwang; Pratiti Bandopadhayay; Christian Bowman-Colin; Jennifer Kutt; Jennifer Curtis; Huiying Piao; Laura C Wong; Andrew L Kung; Rameen Beroukhim; James E Bradner; Ronny Drapkin; William C Hahn; Joyce F Liu; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

6.  Transcription of PIK3CD in human brain and schizophrenia: regulation by proinflammatory cytokines.

Authors:  Veronica L Hood; Ralph Berger; Robert Freedman; Amanda J Law
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

7.  Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.

Authors:  D Escobar-Zarate; Y-P Liu; L Suksanpaisan; S J Russell; K-W Peng
Journal:  Cancer Gene Ther       Date:  2013-09-13       Impact factor: 5.987

8.  Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter.

Authors:  Maria A Whitehead; Michele Bombardieri; Costantino Pitzalis; Bart Vanhaesebroeck
Journal:  Biochem J       Date:  2012-05-01       Impact factor: 3.857

Review 9.  Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer.

Authors:  Zahava Siegfried; Serena Bonomi; Claudia Ghigna; Rotem Karni
Journal:  Int J Cell Biol       Date:  2013-09-03

10.  Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.

Authors:  Yung-Che Chen; Chang-Chun Hsiao; Kuang-Den Chen; Yu-Chiang Hung; Ching-Yuan Wu; Chien-Hao Lie; Shih-Feng Liu; Ming-Tse Sung; Chung-Jen Chen; Ting-Ya Wang; Jen-Chieh Chang; Petrus Tang; Wen-Feng Fang; Yi-Hsi Wang; Yu-Hsiu Chung; Tung-Ying Chao; Sum-Yee Leung; Mao-Chang Su; Chin-Chou Wang; Meng-Chih Lin
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.